Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CSTL 
Castle Biosciences Inc (CSTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: CSTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.97% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 570.85M USD | Price to earnings Ratio 32.29 | 1Y Target Price 38.89 |
Price to earnings Ratio 32.29 | 1Y Target Price 38.89 | ||
Volume (30-day avg) 460289 | Beta 0.98 | 52 Weeks Range 16.96 - 35.84 | Updated Date 03/31/2025 |
52 Weeks Range 16.96 - 35.84 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.49% | Operating Margin (TTM) 4.69% |
Management Effectiveness
Return on Assets (TTM) 1.1% | Return on Equity (TTM) 4.31% |
Valuation
Trailing PE 32.29 | Forward PE - | Enterprise Value 304636744 | Price to Sales(TTM) 1.72 |
Enterprise Value 304636744 | Price to Sales(TTM) 1.72 | ||
Enterprise Value to Revenue 0.92 | Enterprise Value to EBITDA 7.99 | Shares Outstanding 28514100 | Shares Floating 27722557 |
Shares Outstanding 28514100 | Shares Floating 27722557 | ||
Percent Insiders 3.35 | Percent Institutions 93.97 |
Analyst Ratings
Rating 4.89 | Target Price 41.56 | Buy 1 | Strong Buy 8 |
Buy 1 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Castle Biosciences Inc
Company Overview
History and Background
Castle Biosciences was founded in 2008 and is based in Friendswood, Texas. The company is focused on providing diagnostic and prognostic information to improve cancer treatment decisions. It has grown through internal development and strategic acquisitions.
Core Business Areas
- Dermatologic Cancers: Focused on providing genomic tests to guide treatment decisions for patients with cutaneous melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma.
- Gastrointestinal Cancers: Offers genomic tests to improve risk stratification and treatment decisions for patients with esophageal cancer and Barrett's esophagus.
- Uveal Melanoma: Provides diagnostic and prognostic testing to help improve treatment for patients with uveal melanoma, a rare eye cancer
Leadership and Structure
Derek J. Maetzold is the President and CEO. The company has a typical corporate structure with a board of directors overseeing executive management.
Top Products and Market Share
Key Offerings
- DecisionDx-Melanoma: A gene expression profile test that predicts the risk of metastasis in patients with cutaneous melanoma. Competitors include Myriad Genetics (now Labcorp) and Interpace Biosciences. Market Share is estimated to be around 50-60% of the market for gene expression profile testing in cutaneous melanoma. Revenue generated by Melanoma related products accounts for the majority of the company revenue. Number of users based on test reports submitted from hospitals and clinics.
- DecisionDx-SCC: A gene expression profile test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma. Competitors include numerous pathology labs doing traditional risk assessments. DecisionDx-SCC has an increasing penetration in this market. Number of users based on test reports submitted from hospitals and clinics.
- TissueCypher Barrettu2019s Esophagus Assay: A test that assesses the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrettu2019s esophagus. Competitors include Exact Sciences' Cologuard and other endoscopic surveillance methods. Number of users based on test reports submitted from hospitals and clinics.
Market Dynamics
Industry Overview
The market for cancer diagnostics and prognostics is growing rapidly, driven by advancements in genomics and personalized medicine. It is highly competitive, with established players and emerging companies.
Positioning
Castle Biosciences focuses on providing clinically actionable genomic information to improve treatment decisions. Their competitive advantage lies in their proprietary tests, clinical validation data, and focus on specific cancers.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the billions of dollars. Castle Biosciences is positioned to capture a significant share of this market through its expanding product portfolio and growing market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary genomic tests
- Clinical validation data
- Focus on specific cancers
- Strong reimbursement coverage
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Dependence on reimbursement policies
- Relatively small company size
- Limited marketing and sales resources compared to larger competitors
Opportunities
- Expanding product portfolio through internal development and acquisitions
- Increasing market penetration
- Entering new geographic markets
- Developing partnerships with pharmaceutical companies
- Further validating existing products through clinical studies
Threats
- Competition from larger diagnostic companies
- Changes in reimbursement policies
- Technological advancements that could render their tests obsolete
- Failure to obtain regulatory approvals for new products
- Economic downturn that could reduce healthcare spending
Competitors and Market Share
Key Competitors
- ESR (Exact Sciences Corp)
- L (Labcorp)
Competitive Landscape
Castle Biosciences has a strong position in the dermatologic cancer diagnostics market. They need to continue to innovate and expand its product portfolio to remain competitive.
Major Acquisitions
MyPath Laboratories
- Year: 2021
- Acquisition Price (USD millions): 46.4
- Strategic Rationale: Expanded Castle Biosciences' portfolio of dermatopathology tests and strengthened its position in the dermatologic cancer market.
Growth Trajectory and Initiatives
Historical Growth: Castle Biosciences has experienced strong revenue growth in recent years, driven by increasing adoption of its genomic tests.
Future Projections: Analysts expect Castle Biosciences to continue to grow rapidly in the coming years, driven by its expanding product portfolio and increasing market penetration.
Recent Initiatives: Recent initiatives include the acquisition of diagnostic companies and the development of new genomic tests for various cancers.
Summary
Castle Biosciences has a strong position in providing genomic information to improve cancer treatment decisions. The company's strength lies in its proprietary tests and clinical validation data. Areas to watch are competition from larger diagnostic companies, changes in reimbursement policies, and technological advancements. Success is driven by expanding product portfolio and market penetration.
Similar Companies
L
Loews Corp
L
Loews Corp
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Castle Biosciences Inc
Exchange NASDAQ | Headquaters Friendswood, TX, United States | ||
IPO Launch date 2019-07-25 | Founder, CEO, President & Director Mr. Derek J. Maetzold | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 761 | Website https://castlebiosciences.com |
Full time employees 761 | Website https://castlebiosciences.com | ||
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.